镰状细胞病孕妇可预测母婴不良妊娠结局
该回顾性队列研究纳入199例镰状细胞病孕妇,利用常规临床和实验室数据构建母婴不良结局预测模型。71%发生母体不良事件,45%发生胎儿不良事件。
要点
- 孕早期低血红蛋白、孕前需住院的血管闭塞事件、多次输血、SCD基因型和既往心脏并发症可预测母体风险。
- 年轻年龄和SCD基因型可早期预测胎儿风险(模型F1)。
- 加入母体事件和高乳酸脱氢酶可随孕周重新评估胎儿风险(模型F2)。
核心结论
- 常规临床和实验室数据可预测镰状细胞病孕妇的母体和胎儿不良妊娠结局。
研究设计与样本
- 回顾性队列研究,纳入199例镰状细胞病孕妇,采用广义估计方程逻辑回归构建预测模型并按孕妇聚类。
主要发现
- 199例妊娠中,71%出现母体不良结局,45%出现胎儿不良结局。
关键数值与推荐
- 母体不良事件包括急性贫血、心/肺/肝胆/骨骼肌/皮肤/脾/神经/肾并发症、多器官衰竭、静脉血栓栓塞、需住院的血管闭塞事件、红细胞输注、死亡或妊娠期高血压疾病。
- 胎儿不良事件包括早产、小于胎龄儿或围产期死亡。
临床怎么用
- 模型可早期识别不良事件高风险的镰状细胞病孕妇,以便早期针对性干预。
- 持续胎儿风险评估有助于加强监测和优化分娩时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to identify risk factors for adverse outcomes in pregnancies of women with sickle cell disease (SCD) and develop risk prediction models. Models were derived from a retrospective cohort of pregnant women with SCD and constructed using generalised estimating equation logistic regression, with clustering by woman. Maternal event(s) consisted of acute anaemia; cardiac, pulmonary, hepatobiliary, musculoskeletal, skin, splenic, neurological or renal complications, multi-organ failure, venous thromboembolism, admission-requiring vaso-occlusive events (VOE), red cell transfusion, mortality or hypertensive disorder of pregnancy. Fetal events included preterm birth, small-for-gestational-age or perinatal mortality. Of 199 pregnancies, 71% and 45% resulted in adverse maternal and fetal outcomes respectively. Low first-trimester haemoglobin, admission-requiring VOE in the year before pregnancy, multiple transfusions before pregnancy, SCD genotype and previous cardiac complications predicted maternal risk. Younger age and SCD genotype allowed early prediction of fetal risk (model-F1). Adding maternal event(s) and high lactate dehydrogenase enabled re-assessment of fetal risk with advancing gestation (model-F2). Models were well calibrated and moderately discriminative for maternal outcome (c-statistic 0·81, cross-validated value 0·79) and fetal outcome (model-F1 c-statistic 0·68, cross-validated value 0·65; model-F2 c-statistic 0·72, cross-validated value 0·68). The models will allow early identification of women with SCD at high risk of adverse events, permitting early targeted interventions and ongoing fetal risk re-assessment enabling intensification of surveillance and optimisation of delivery timing.
引用
- Malinowski AK, Kuo KHM, Tomlinson GA, et al. Distinct maternal and fetal pregnancy outcomes in women with sickle cell disease can be predicted using routine clinical and laboratory data. Br J Haematol. 2021. PMID: 34124774. doi:10.1111/bjh.17607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。